Dallas TX 肾衰竭临床试验
9项针对 肾衰竭的研究正在 Dallas及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
招募中2/3 期
- Dallas V.A. Medical Center, Dallas
- Dallas Nephrology Associates, Dallas
- US Renal Care, Dallas
Pivotal Study of the Velocity™ pAVF System
招募中
- Advanced Dallas Hospital, Dallas
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
招募中1/2 期欢迎健康志愿者
- Research Site, Dallas
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
招募中
- University of Texas Southwestern Medical Center, Dallas
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
招募中
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas
PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis
招募中观察性研究
- Baylor Scott & White Heart and Vascular Hospital - Dallas, Dallas
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
招募中
- Baylor Scott & White Heart and Vascular Hospital, Dallas
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
招募中3 期
- University of Texas Southwestern, Dallas
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
招募中
- Baylor Heart and Vascular, Dallas
其他城市的 肾衰竭试验
- Boston, MA14 项研究
- Houston, TX13 项研究
- New York City, NY7 项研究
- Chicago, IL7 项研究
- Queens, NY6 项研究
- Atlanta, GA5 项研究
- Durham, NC5 项研究
- Baltimore, MD5 项研究
- Phoenix, AZ5 项研究
- Orlando, FL5 项研究
- Mountain View, CA4 项研究
- Jacksonville, FL4 项研究
Dallas的其他研究
- 乳腺癌54 项研究
- 非小细胞肺癌52 项研究
- 心力衰竭42 项研究
- 转移性癌症42 项研究
- 癌症（所有类型）38 项研究
- 前列腺癌36 项研究
- 结直肠癌33 项研究
- 肥胖症31 项研究
- 卵巢癌28 项研究
- 膀胱癌27 项研究
- 肺癌27 项研究
- 子宫内膜癌25 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月1日。每项研究自行设定入选标准，由研究团队决定谁能参与。